Literature DB >> 3458521

High resolution chromosome analysis of constitutional and acquired t(15;17) maps c-erbA to subband 17q11.2.

F Mitelman, G Manolov, Y Manolova, R Billström, S Heim, U Kristoffersson, N Mandahl, M T Ferro, C San Roman.   

Abstract

High resolution chromosome analysis was performed on bone marrow cells from four patients with acute promyelocytic leukemia and t(15;17), and in lymphocytes from two unrelated, phenotypically normal persons with an apparently identical constitutional translocation. Scrutiny of prophase-prometaphase chromosomes localized the breakpoints in all six cases to subbands 15q22.3 and 17q11.2. Molecular genetic studies have localized the oncogene c-erbA to chromosome #17 between the breakpoints of the constitutional and the acquired anomaly. The present results, therefore, map c-erbA to subband 17q11.2.

Entities:  

Mesh:

Year:  1986        PMID: 3458521     DOI: 10.1016/0165-4608(86)90168-8

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  5 in total

1.  Localization of the human chromosome 5q genes Gabra-1, Gabrg-2, Il-4, Il-5, and Irf-1 on mouse chromosome 11.

Authors:  M S Buckwalter; A C Lossie; L M Scarlett; S A Camper
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

Review 2.  Mouse chromosome 11.

Authors:  A M Buchberg; M S Buckwalter; S A Camper
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

Review 3.  Mouse chromosome 11.

Authors:  A M Buchberg; J J Moskow; M S Buckwalter; S A Camper
Journal:  Mamm Genome       Date:  1991       Impact factor: 2.957

4.  Evolution of multiple cytogenetic clones and leukemic transformation in a case of myelodysplastic syndrome.

Authors:  E Donti; G V Donti; F Falzetti; A Rosetti; F Grignani; A Tabilio
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

5.  Precise localization of NF1 to 17q11.2 by balanced translocation.

Authors:  D H Ledbetter; D C Rich; P O'Connell; M Leppert; J C Carey
Journal:  Am J Hum Genet       Date:  1989-01       Impact factor: 11.025

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.